FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Hammerer

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Prostate

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Laurent Boccon-Gibod; Peter Hammerer; Stephan Madersbacher; Nicolas Mottet; Tommaso Prayer-Galetti; Ulf Tunn
The role of intermittent androgen deprivation in prostate cancer.
Bob Djavan; Vincent Ravery; Bernardo Rocco; Alexandre R Zlotta; Maurizio Brausi; Markus Margreiter; Peter Hammerer; Amir Kaisary; Theodore Anagnostou; Imre Romics; Piotr Dobronski; Ottavio De Cobelli; Michael Marberger
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005.
Christof Börgermann; M Sieverding; P Fornara; Markus Graefen; Peter Hammerer; A Semjonow; F Schröder; Herbert Rübben
[PSA 2010--the beginning of a new era in early detection of prostate cancer].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Hammerer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Laurent Boccon-Gibod; Peter Hammerer; Stephan Madersbacher; Nicolas Mottet; Tommaso Prayer-Galetti; Ulf Tunn
The role of intermittent androgen deprivation in prostate cancer.
BJU international 2007;100(4):738-43.
2007: Bob Djavan; Vincent Ravery; Bernardo Rocco; Alexandre R Zlotta; Maurizio Brausi; Markus Margreiter; Peter Hammerer; Amir Kaisary; Theodore Anagnostou; Imre Romics; Piotr Dobronski; Ottavio De Cobelli; Michael Marberger
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005.
BJU international 2007;100 Suppl 2():22-5.
2006: Christof Börgermann; M Sieverding; P Fornara; Markus Graefen; Peter Hammerer; A Semjonow; F Schröder; Herbert Rübben
[PSA 2010--the beginning of a new era in early detection of prostate cancer].
Der Urologe. Ausg. A 2006;45 Suppl 4():127-33.
2006: Nicolas Mottet; Tommaso Prayer-Galetti; Peter Hammerer; Michael W Kattan; Ulf Tunn
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
BJU international 2006;98(1):20-7.
2006: Peter Hammerer; Michael W Kattan; Nicolas Mottet; Tommaso Prayer-Galetti
Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
BJU international 2006;98(1):11-9.
2005: Thomas Keller; Hermann Butz; Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Klaus Jung
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
Clinical chemistry 2005;51(3):532-9.
2004: Herbert Augustin; Andreas Erbersdobler; Peter Hammerer; Markus Graefen; Hartwig Huland
Prostate cancers in the transition zone: Part 2; clinical aspects.
BJU international 2004;94(9):1226-9.
2004: Martin G Friedrich; Marieta I Toma; Susan Petri; Jonathan C Cheng; Peter Hammerer; Andreas Erbersdobler; Hartwig Huland
Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
European urology 2004;45(6):737-43.
2004: Laurent Boccon-Gibod; W B Djavan; Peter Hammerer; W Hoeltl; Michael W Kattan; Tommaso Prayer-Galetti; P Teillac; Ulf Tunn
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
International journal of clinical practice 2004;58(4):382-90.
2004: Albrecht Röpke; Andreas Erbersdobler; Peter Hammerer; Jüri Palisaar; Kerstin John; Markus Stumm; Peter Wieacker
Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy.
The Prostate 2004;59(1):59-68.
2004: Peter Hammerer; Herbert Augustin; Jakob Blonski; Markus Graefen; Alexander Haese; Andreas Erbersdobler; Fedor Daghofer; Hartwig Huland
[Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system].
Der Urologe. Ausg. A 2004;43(3):307-12.
2004: Ilias Cagiannos; Pierre I Karakiewicz; Markus Graefen; James A Eastham; Makoto Ohori; Farhang Rabbani; Victor E Reuter; Thomas Wheeler; Patrick A Kupelian; Eric Klein; Hartwig Huland; Peter Hammerer; Andreas Erbersdobler; Fritz Schroeder; Mark F Wildhagen; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Christopher G Morash; Peter T Scardino; Michael W Kattan
Is year of radical prostatectomy a predictor of outcome in prostate cancer?
The Journal of urology 2004;171(2 Pt 1):692-6.
2004: Stefan H Hautmann; Martin G Friedrich; Salvador Fernandez; Thomas Steuber; Peter Hammerer; Peter M Braun; Klaus-Peter Jünemann; Hartwig Huland
Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stones.
Urologia internationalis 2004;73(3):238-43.
2004: Peter Hammerer
pT0 after radical prostatectomy: overtreatment for insignificant prostate cancer?
European urology 2004;45(1):35.
2004: Markus Graefen; Makoto Ohori; Pierre I Karakiewicz; Ilias Cagiannos; Peter Hammerer; Alexander Haese; Andreas Erbersdobler; Rolf-Peter Henke; Hartwig Huland; Thomas M Wheeler; Kevin Slawin; Peter T Scardino; Michael W Kattan
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
The Journal of urology 2004;171(1):200-3.
2003: Herbert Augustin; Peter Hammerer
Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2003;55(4):251-61.
2003: Ilias Cagiannos; Pierre I Karakiewicz; James A Eastham; Makoto Ohori; Farhang Rabbani; Claudia Gerigk; Victor E Reuter; Markus Graefen; Peter Hammerer; Andreas Erbersdobler; Hartwig Huland; Patrick A Kupelian; Eric Klein; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Christopher G Morash; Peter T Scardino; Michael W Kattan
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
The Journal of urology 2003;170(5):1798-803.
2003: Herbert Augustin; Peter Hammerer; Markus Graefen; Jüri Palisaar; Fedor Daghofer; Hartwig Huland; Andreas Erbersdobler
Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.
Journal of cancer research and clinical oncology 2003;129(11):662-8.
2003: Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Virgilijus Klevecka; Kasra Taymoorian; Dietmar Schnorr; Franz Recker; Stefan A Loening; Klaus Jung
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
The Journal of urology 2003;170(4 Pt 1):1175-9.
2003: Herbert Augustin; Markus Graefen; Jüri Palisaar; Jakob Blonski; Andreas Erbersdobler; Fedor Daghofer; Hartwig Huland; Peter Hammerer
Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2860-8.
2003: Herbert Augustin; Peter Hammerer; Jakob Blonski; Markus Graefen; Jüri Palisaar; Fedor Daghofer; Hartwig Huland; Andreas Erbersdobler
Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?
Urology 2003;62(1):79-85.
2003: Markus Kuczyk; Levent Turkeri; Peter Hammerer; Vincent Ravery
Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
European urology 2003;44(1):57-64.
2003: Markus Graefen; Herbert Augustin; P I Karakiewicz; Peter Hammerer; Alexander Haese; Jüri Palisaar; S Fernandez; Joachim Noldus; Andreas Erbersdobler; Ilias Cagiannos; Peter T Scardino; Michael W Kattan; Hartwig Huland
[Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy].
Der Urologe. Ausg. A 2003;42(5):685-92.
2003: Herbert Augustin; Peter Hammerer; Markus Graefen; Andreas Erbersdobler; Jakob Blonski; Jüri Palisaar; Fedor Daghofer; Hartwig Huland
Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction.
European urology 2003;43(5):455-60.
2003: Herbert Augustin; Andreas Erbersdobler; Markus Graefen; T Jaekel; Alexander Haese; Hartwig Huland; Peter Hammerer
Differences in biopsy features between prostate cancers located in the transition and peripheral zone.
BJU international 2003;91(6):477-81.
2003: Herbert Augustin; Andreas Erbersdobler; Markus Graefen; Salvador Fernandez; Jüri Palisaar; Hartwig Huland; Peter Hammerer
Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones.
The Prostate 2003;55(1):48-54.
2003: Alexander Haese; Manisha Chaudhari; M Craig Miller; Jonathan I Epstein; Hartwig Huland; Jüri Palisaar; Markus Graefen; Peter Hammerer; Edward C Poole; Gerard J O'Dowd; Alan W Partin; Robert W Veltri
Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Cancer 2003;97(4):969-78.
2003: Martin G Friedrich; Angelika Hellstern; Marieta I Toma; Peter Hammerer; Hartwig Huland
Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?
European urology 2003;43(2):146-50; discussion 150-1.
2003: Herbert Augustin; Peter Hammerer; Markus Graefen; Jüri Palisaar; Joachim Noldus; Salvador Fernandez; Hartwig Huland
Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002.
European urology 2003;43(2):113-8.
2003: Markus Graefen; Herbert Augustin; Pierre I Karakiewicz; Peter Hammerer; Alexander Haese; Jüri Palisaar; Jakob Blonski; Salvador Fernandez; Andreas Erbersdobler; Hartwig Huland
Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.
European urology 2003;43(1):6-10; discussion 11.
2002: Thomas Steuber; Paulina Nurmikko; Alexander Haese; Kim Pettersson; Markus Graefen; Peter Hammerer; Hartwig Huland; Hans Lilja
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
The Journal of urology 2002;168(5):1917-22.
2002: Bob Djavan; Mesut Remzi; Alexandre R Zlotta; Vincent Ravery; Peter Hammerer; Andreas Reissigl; Piotr Dobronski; Amir Kaisary; Michael Marberger
Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Urology 2002;60(4 Suppl 1):4-9.
2002: Joachim Noldus; Uwe Michl; Markus Graefen; Alexander Haese; Peter Hammerer; Hartwig Huland
Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy.
European urology 2002;42(2):118-24.
2002: Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Eric Klein; Patrick A Kupelian; Donald G Skinner; Gary Lieskovsky; Bernard H Bochner; Hartwig Huland; Peter Hammerer; Alexander Haese; Andreas Erbersdobler; James A Eastham; Jean de Kernion; Thomas Cangiano; Fritz H Schröder; Mark F Wildhagen; Theo Van der Kwast; Peter T Scardino; Michael W Kattan
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3206-12.
2002: Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Peter Hammerer; Alexander Haese; Jüri Palisaar; Salvador Fernandez; Jochen Noldus; Andreas Erbersdobler; Hartwig Huland; Peter T Scardino; Michael W Kattan
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.
Urologic oncology 2002;7(4):141-6.
2002: Ilias Cagiannos; Markus Graefen; Pierre I Karakiewicz; Makoto Ohori; James A Eastham; Farhang Rabbani; William Fair; Thomas M Wheeler; Peter Hammerer; Alexander Haese; Andreas Erbersdobler; Hartwig Huland; Peter T Scardino; Michael W Kattan
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2025-30.
2002: Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Peter Hammerer; Alexander Haese; Jüri Palisaar; Edith Huland; Peter T Scardino; Michael W Kattan; Hartwig Huland
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
The Journal of urology 2002;167(3):1306-9.
2002: Hartwig Huland; Markus Graefen; Alexander Haese; Peter Hammerer; Jüri Palisaar; Uwe Pichlmeier; Rolf-Peter Henke; Andreas Erbersdobler; Edith Huland; Hans Lilja
Prediction of tumor heterogeneity in localized prostate cancer.
The Urologic clinics of North America 2002;29(1):213-22.
2002: R Jüri Palisaar; Markus Graefen; Pierre I Karakiewicz; Peter Hammerer; Edith Huland; Alexander Haese; Salvador Fernandez; Andreas Erbersdobler; Rolf-Peter Henke; Hartwig Huland
Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.
European urology 2002;41(2):155-61.
2002: Stefan Conrad; Markus Graefen; Uwe Pichlmeier; Rolf-Peter Henke; Andreas Erbersdobler; Peter Hammerer; Hartwig Huland
Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma.
The Journal of urology 2002;167(2 Pt 1):521-5.
2002: Andreas Erbersdobler; S Huhle; Jüri Palisaar; Markus Graefen; Peter Hammerer; Joachim Noldus; Hartwig Huland
Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
Prostate cancer and prostatic diseases 2002;5(4):279-84.
2002: Andreas Erbersdobler; Henning Fritz; Silvia Schnöger; Markus Graefen; Peter Hammerer; Hartwig Huland; Rolf-Peter Henke
Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.
European urology 2002;41(1):40-6.
2001: Martin G Friedrich; C Blind; Karin Milde-Langosch; Andreas Erbersdobler; Stefan Conrad; Thomas Löning; Peter Hammerer; Hartwig Huland
Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
European urology 2001;40(5):518-24.
2001: Michael Lein; Klaus Jung; Peter Hammerer; M Graefen; Axel Semjonow; P Stieber; M Ossendorf; Hans-Joachim Luboldt; Brigitte Brux; Carsten Stephan; Dietmar Schnorr; Stefan A Loening
A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
The Prostate 2001;47(2):77-84.
2001: W Prange; Andreas Erbersdobler; Peter Hammerer; Markus Graefen; Stefan H Hautmann; RE Hautmann; Hartwig Huland; Rolf-Peter Henke
High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens.
European urology 2001;39 Suppl 4():30-1.
2001: Joachim Noldus; Uwe Michl; Markus Graefen; Alexander Haese; Peter Hammerer; S Fernandez; Hartwig Huland
[Nerve-sparing radical retropubic prostatectomy. Results of a patient survey].
Der Urologe. Ausg. A 2001;40(2):102-6.
2001: W Prange; Andreas Erbersdobler; Peter Hammerer; Markus Graefen; Stefan H Hautmann; RE Hautmann; Hartwig Huland; Rolf-Peter Henke
Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens.
Urology 2001;57(3):486-90.
2001: Markus Graefen; Alexander Haese; Uwe Pichlmeier; Peter Hammerer; Joachim Noldus; K Butz; Andreas Erbersdobler; Rolf-Peter Henke; Uwe Michl; S Fernandez; Hartwig Huland
A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
The Journal of urology 2001;165(3):857-63.
2001: Martin G Friedrich; Sabine Riethdorf; Andreas Erbersdobler; C Tiemer; Hartwig Schwaibold; J K Sölter; Edith Huland; Lutz Riethdorf; Stefan Conrad; Peter Hammerer; Hartwig Huland
Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
European urology 2001;39(2):159-66.
2000: Peter Hammerer; Markus Graefen; Rolf-Peter Henke; Alexander Haese; Jüri Palisaar; Edith Huland; Hartwig Huland
Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.
Anticancer research 2000;20(6D):5253-5.
2000: Jan-Henner Wurmbach; Peter Hammerer; Sema Sevinc; Hartwig Huland; Süleyman Ergün
The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma.
Anticancer research 2000;20(6D):5217-20.
2000: Peter Hammerer; Markus Graefen; Thomas Steuber; Hartwig Huland
[Chemoprevention of prostatic carcinoma].
Der Urologe. Ausg. A 2000;39(4):304-8.
2000: Joachim Noldus; Markus Graefen; Alexander Haese; Rolf-Peter Henke; Peter Hammerer; Hartwig Huland
Stage migration in clinically localized prostate cancer.
European urology 2000;38(1):74-8.
2000: Markus Graefen; Peter Hammerer; Alexander Haese; Hartwig Huland
[Therapeutic options in hormone refractory prostate carcinoma].
Der Urologe. Ausg. A 2000;39(3):267-73.
1999: H Heinzer; Peter Hammerer; H Huland
Anatomy and physiology of the male urethral sphincter and its preservation in prostatic surgery.
Urological research 1999;27(6):404-8.
1998: Rolf-Peter Henke; Peter Hammerer; Markus Graefen; Andreas Erbersdobler; M Neumann; J Berger; Hartwig Huland
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.
Cancer 1998;83(5):977-88.
1998: Stefan Conrad; Markus Graefen; Uwe Pichlmeier; Rolf-Peter Henke; Peter Hammerer; Hartwig Huland
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
The Journal of urology 1998;159(6):2023-9.
1998: I Lange; Peter Hammerer; Cornelius Knabbe; Markus Graefen; M Schmahl; Hartwig Huland
[Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia].
Der Urologe. Ausg. A 1998;37(2):199-202.
1998: Joachim Noldus; Markus Graefen; Peter Hammerer; Rolf-Peter Henke; Hartwig Huland
[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma].
Der Urologe. Ausg. A 1998;37(2):195-8.
1998: Markus Graefen; Peter Hammerer; Uwe Michl; Joachim Noldus; Alexander Haese; Rolf-Peter Henke; Edith Huland; Hartwig Huland
Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.
Urology 1998;51(3):437-42.
1998: Hans Heinzer; Peter Hammerer; Markus Graefen; Hartwig Huland
Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas.
European urology 1998;33(1):86-90.
1997: Andreas Erbersdobler; Peter Hammerer; Hartwig Huland; Rolf-Peter Henke
Numerical chromosomal aberrations in transition-zone carcinomas of the prostate.
The Journal of urology 1997;158(4):1594-8.
1997: Hans Heinzer; M Graefen; Joachim Noldus; Peter Hammerer; Hartwig Huland
Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience.
Urologia internationalis 1997;59(1):30-3.
1997: Joachim Noldus; Peter Hammerer; Markus Graefen; Hartwig Huland
Surgical therapy for localized prostatic carcinoma.
Journal of cancer research and clinical oncology 1997;123(3):180-4.
1997: Peter Hammerer; Hartwig Huland
Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy.
The Journal of urology 1997;157(1):233-6.
1996: Peter Hammerer; U Michl; Wolf-Hartmut Meyer-Moldenhauer; Hartwig Huland
Urethral closure pressure changes with age in men.
The Journal of urology 1996;156(5):1741-3.
1996: Hartwig Huland; Peter Hammerer; Rolf-Peter Henke; Edith Huland
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
The Journal of urology 1996;155(4):1344-7.
1995: Peter Hammerer; Rolf-Peter Henke; D Hübner; Hartwig Huland
[Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma].
Der Urologe. Ausg. A 1995;34(5):413-8.
1995: Peter Hammerer; D Hübner; Dietrich Gonnermann; Hartwig Huland
[Perioperative and postoperative complications of pelvic lymphadenectomy and radical prostatectomy in 320 consecutive patients].
Der Urologe. Ausg. A 1995;34(4):334-42.
1995: Peter Hammerer; Hartwig Huland
[Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
Der Urologe. Ausg. A 1995;34(4):283-9.
1994: D Hübner; Rolf-Peter Henke; Peter Hammerer; Hartwig Huland
[Morphologic results of 106 consecutive radical prostatectomy specimen of patients with clinical stage B1-B3 (T2a-c) and histologically negative lymph nodes in the fossa obturatoria].
Der Urologe. Ausg. A 1994;33(6):497-504.
1994: Rolf-Peter Henke; E Krüger; N Ayhan; D Hübner; Peter Hammerer; Hartwig Huland
Immunohistochemical detection of p53 protein in human prostatic cancer.
The Journal of urology 1994;152(4):1297-301.
1994: Rolf-Peter Henke; E Krüger; N Ayhan; D Hübner; Peter Hammerer
Frequency and distribution of numerical chromosomal aberrations in prostatic cancer.
Human pathology 1994;25(5):476-84.
1993: Rolf-Peter Henke; E Krüger; N Ayhan; D Hübner; Peter Hammerer
Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics.
Virchows Archiv. A, Pathological anatomy and histopathology 1993;422(1):61-6.
1993: Rolf-Peter Henke; E Krüger; N Ayhan; D Hübner; Peter Hammerer
[Significance of numerical chromosome aberrations in prostate cancer].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1993;77():133-7.
1988: R Arndt; M Weiss; Peter Hammerer; Hartwig Huland; A Kruppa; H Krämer-Hansen
Expression of immunoregulatory molecules on tubular cells and lymphocytes in fine-needle aspiration biopsy: early diagnostic marker for renal allograft rejection.
Transplantation proceedings 1988;20(4):614-6.
1988: Peter Hammerer; H Krämer-Hansen; B Kremer; D Henne-Bruns; G Klöppel; R Arndt; Hartwig Huland
Aspiration cytology of liver transplants.
Transplantation proceedings 1988;20(4):640-1.
1988: R Arndt; Hans Heinzer; Peter Hammerer; Hartwig Huland; T Löhning; H Krämer-Hansen
Identification of virus DNA in kidney transplants by fine-needle aspiration biopsy.
Transplantation proceedings 1988;20(4):581-3.
1988: Peter Hammerer; R Arndt; H Krämer-Hansen; Hartwig Huland; H Klosterhalfen
Consecutive selective aspiration cytology of renal cortex and renal medulla in kidney transplants.
Transplantation proceedings 1988;20(4):577-8.
1988: R Arndt; Peter Hammerer; Edith Huland; H Krämer-Hansen; Hartwig Huland
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulin.
Urologia internationalis 1988;43(3):139-44.